ERBB2 and cancer: Our previous work demonstrated the utility of T-DM1 as a targeted enhancer of oncolytic vesicular stomatitis virus (VSVΔ51) in HER2-amplified cancers (13), as a result of mechanistic synergy between microtubule destabilizing agents and VSVΔ51 (14).